...
首页> 外文期刊>Health Research Policy and Systems >Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997–2013
【24h】

Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997–2013

机译:将研究投资与英国机构的研究投资与结核病,艾滋病毒和疟疾出版的研究投资:1997 - 2013年的系统分析

获取原文
           

摘要

The “Unfinished Agenda” of infectious diseases is of great importance to policymakers and research funding agencies that require ongoing research evidence on their effective management. Journal publications help effectively share and disseminate research results to inform policy and practice. We assess research investments to United Kingdom institutions in HIV, tuberculosis and malaria, and analyse these by numbers of publications and citations and by disease and type of science. Information on infection-related research investments awarded to United Kingdom institutions across 1997–2010 were sourced from funding agencies and individually categorised by disease and type of science. Publications were sourced from the Scopus database via keyword searches and filtered to include only publications relating to human disease and containing a United Kingdom-based first and/or last author. Data were matched by disease and type of science categories. Investment (United Kingdom pounds) and publications were compared to generate an ‘investment per publication’ metric; similarly, an ‘investment per citation’ metric was also developed as a measure of the usefulness of research. Total research investment for all three diseases was £1.4 billion, and was greatest for HIV (£651.4 million), followed by malaria (£518.7 million) and tuberculosis (£239.1 million). There were 17,271 included publications, with 9,322 for HIV, 4,451 for malaria, and 3,498 for tuberculosis. HIV publications received the most citations (254,949), followed by malaria (148,559) and tuberculosis (100,244). According to UK pound per publication, tuberculosis (£50,691) appeared the most productive for investment, compared to HIV (£61,971) and malaria (£94,483). By type of science, public health research was most productive for HIV (£27,296) and tuberculosis (£22,273), while phase I–III trials were most productive for malaria (£60,491). According to UK pound per citation, tuberculosis (£1,797) was the most productive area for investment, compared to HIV (£2,265) and malaria (£2,834). Public health research was the most productive type of science for HIV (£2,265) and tuberculosis (£1,797), whereas phase I–III trials were most productive for malaria (£1,713). When comparing total publications and citations with research investment to United Kingdom institutions, tuberculosis research appears to perform best in terms of efficiency. There were more public health-related publications and citations for HIV and tuberculosis than other types of science. These findings demonstrate the diversity of research funding and outputs, and provide new evidence to inform research investment strategies for policymakers, funders, academic institutions, and healthcare organizations.
机译:传染病的“未完成的议程”对政策制定者和研究资金机构非常重视,需要对其有效管理的持续研究证据进行持续的研究。期刊出版物有效地有效地分享和传播研究成果,以告知政策和实践。我们评估对艾滋病毒,结核病和疟疾的英国机构的研究投资,并通过疾病和科学类型分析这些出版物和引用的数量。有关涉及1997 - 2010年的英国机构的感染相关研究投资的信息来自资金机构,并被疾病和科学类型单独分类。通过关键字搜索从Scopus数据库中源于Scopus数据库,并过滤仅包括与人类疾病有关的出版物,并包含英国的第一和/或持续作者。数据与疾病和科学类别类型相匹配。比较投资(英国磅)和出版物,以产生“每刊登投资”公制;同样,还制定了“每个引文的投资”作为研究有用性的衡量标准。所有三种疾病的研究总投资为14亿英镑,最大的艾滋病毒(651.4百万英镑),其次是疟疾(518.7百万英镑)和结核病(23910万英镑)。有17,271名出版物,艾滋病毒治疗艾滋病毒,疟疾4,451和结核病3,498。 HIV出版物获得了最多的引用(254,949),其次是疟疾(148,559)和结核病(100,244)。根据英镑的每次出版物,结核病(50,691英镑)似乎对投资最富有成效,而艾滋病毒(61,971英镑)和疟疾(94,483英镑)。根据科学类型,公共卫生研究对于艾滋病毒(27,296英镑)和结核病(22,273英镑)最富有成效,而I-III阶段试验最为富含疟疾(60,491英镑)。根据英国/英镑的统计,与艾滋病毒(2,265英镑)和疟疾(£2,834)相比,结核病(1,797英镑)是最富有成效的投资地区。公共卫生研究是艾滋病毒(2,265英镑)和结核病(1,797英镑)的最富有成效的科学类型,而第I-III款试验最为富含疟疾(1,713英镑)。在将出版物总额与研究投资与英国机构进行比较时,肺结核研究似乎在效率方面表现最佳。与其他类型的科学有更多的公共卫生相关的出版物和引用的艾滋病毒和结核病。这些调查结果证明了研究资金和产出的多样性,并提供了新的证据,以告知政策制定者,资助者,学术机构和医疗组织的研究投资策略。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号